RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue. First-in-class, steroid-free compound reduced inflammatory and fibrotic biomarkers in human lung tissue furthering support as a new advancement in the treatment of deadly lung diseases. Click to read the full press release.
关于我们
The mission of RS BioTherapeutics is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation. RS BioTherapeutics’ first investigational compound (RSBT-001) is a first-in-class therapeutic in development as an alternative to corticosteroids for the treatment of respiratory diseases characterized by pulmonary inflammation including COPD, Idiopathic Pulmonary Fibrosis, SARS-COV-2, Cystic Fibrosis, Asthma, Bronchitis, and Acute Respiratory Distress Syndrome. RSBT-001 harnesses the immune modulating power of specific, anti-inflammatory cannabinoids delivered by a proprietary, polarity adaptive transport mechanism and reduces pulmonary inflammation by targeting the inflammatory cascade in the lungs at multiple levels. RS BioTherapeutics is targeting an IND filing for RSBT-001 in early 2025.
- 网站
-
https://www.RSBioTherapeutics.com
RS BioTherapeutics, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Cumberland，MD
- 类型
- 私人持股
地点
-
主要
获取路线
US，MD，Cumberland，21502
RS BioTherapeutics, Inc.员工
动态
-
As the RS Bio Team shuts down for the holidays to spend valued time with our families and friends, we reflect on an incredible year for our first-in-class, steroid-free, agent in development for pulmonary inflammation-based diseases. Our progress this year culminated with exciting data as to the effect RSBT-001 has shown in impacting pulmonary inflammatory biomarkers in our precision cut human lung tissue study. More on that in the coming year but for now, we wish our shareholders, advisors, partners, and supporters an enjoyable and blessed holiday season!
-
-
Advances in research often build upon the selfless contributions of individuals who donated their organs to science, a profound act that drives progress in understanding and innovation. It’s crucial to honor their legacy by acknowledging these sacrifices as we strive to make a difference in the lives of people suffering from pulmonary inflammation.
We are undertaking an exciting research initiative involving precision cut human lung slices in RS BioTherapeutics, Inc. continued development of our first-in-class, steroid-free agent for millions of patients suffering from diseases characterized by pulmonary inflammation including COPD - the fourth leading cause of death in the world. Last week we were notified that a “suitable” lung had been received by our research partner. While we were excited to get the research underway, our enthusiasm was tempered by the knowledge of the events that had to occur for this lung to become available and us to initiate our research. We are humbled and grateful that the individual whose lung was donated for medical science chose to be an organ donor so that the quality of life for millions of patients suffering from deadly lung diseases might be improved. Our thoughts, prayers, and sincere appreciation are with this individual, their family and friends. We pray that the fact their loved one continues to make a difference in the world helps to ease their pain and loss.
-
We at RS BioTherapeutics, Inc. are incredibly thankful for the service and sacrifices of our country’s veterans and those who continue to serve to protect our country and the liberties we hold so dear. Hoping they and all have a safe and enjoyable Veterans Day.
-
-
At RS Bio, we are constantly striving to optimize the drug development process by implementing strategies offering high translational value. Studies using human lung slices, often referred to as Precision Cut Lung Slices (PCLS), do just that. PCLS are primarily used to investigate various aspects of lung function, disease mechanisms, and drug responses in a physiologically relevant ex vivo model, including areas like inflammation and fibrosis. They can also be used to study the effects of lung diseases like COPD and pulmonary fibrosis by analyzing cellular responses within the tissue slices to different stimuli. The figure below from a 2024 article by Cynthia Koziol-White from the Rutgers Institute for Translational Medicine and Science highlights the range of processes that can be measured utilizing PCLS. RS BioTherapeutics, Inc. will soon be testing our first-in-class, steroid-free compound for its ability to attenuate inflammation and fibrosis in an inducible, human PCLS model, which is clinically relevant for??COPD and Idiopathic Pulmonary Fibrosis (IPF) respectively. We are optimistic that the high translational value will provide valuable insights for our continued development of RSBT-001 and future clinical trials.? We look forward to sharing those study results in the coming months as we continue to work towards improving the lives of patients suffering from deadly lung diseases like COPD, IPF, and PAH.?
-
-
Did you know September is Pulmonary Fibrosis Awareness Month? This year the theme is “Every breath, every story” and the goal is to showcase how the pulmonary fibrosis community stands together in the fight against this disease. At RS BioTherapeutics, Inc. we are committed to fighting deadly lung diseases by providing an innovative, first-in-class solution for lung diseases characterized by pulmonary inflammation, including COPD, IPF, and more.? The Pulmonary Fibrosis Foundation has put together an incredible campaign to raise awareness and highlight the community. The "30 Facts In 30 Days" series is one of our favorites – below is the first one! Check their page for more. #PFMonth?#BlueUp4PF?#respiratory #research #innovation
As we kick off our 30 Facts In 30 Days series, let's start with the basics: What is pulmonary fibrosis?
-
-
From our CEO, Dean Hart...
Wishing all of you and the dedicated RS BioTherapeutics, Inc. team, our partners, shareholders, and their friends and families a safe and enjoyable Labor Day weekend and holiday! We are taking this long weekend to recharge our batteries as we focus on finishing 2024 strong in developing our lead compound as a new hope for patients suffering from COPD, IPF, and PAH. #rsbiotherapeutics #COPD #IPF #PAH #cannabinoidmedicine #pulmonaryinflammation #pulmonarydiseases
-
-
We are proud to announce that we have submitted two proposals to the Toxic Exposures Research Program (TERP) in support of RSBT-001, a first-in-class therapeutic agent aimed at treating deadly lung diseases associated with pulmonary inflammation. The goals of TERP—preventing, minimizing, and mitigating the impact of military-related toxic exposures—strongly align with our dedication to improving the health and quality of life for those affected by deadly lung conditions. Military personnel are often exposed to a range of harmful substances, leading to complex and debilitating health issues, including chronic lung diseases such as COPD. Our submissions address the long-term impact of these types of exposures. By submitting to TERP, we aim to contribute to the advancement of scientific understanding and the development of effective healthcare solutions to support veterans and active service members who have sacrificed so much.
-
On this Thursday, July 25th, our CEO Dean Hart will host a webinar for our community. Register NOW using the link below to secure your spot! https://lnkd.in/ehXkXmwr This webinar is an excellent opportunity for you to ask questions, engage directly with our CEO, and learn more about how RS BioTherapeutics, Inc. is making a difference in the lives of patients with deadly lung diseases.?
-